Why the study?
Discrepancies exist in current guidelines regarding perioperative evaluation and risk mitigation strategies for ischemic cardiac burden in lung transplant candidates with CAD.
This review summarizes current data on perioperative evaluation, revascularization strategies, and outcomes for lung transplant candidates with coronary artery disease.
Guideline discrepancies for CAD evaluation in lung transplant persist; leaves open standardized perioperative risk mitigation.
Coronary artery disease (CAD) is a pathology often found in patients with end-stage lung disease. Although in the past CAD might have been considered an absolute contraindication, modern revascularization techniques have helped increase the number of transplants performed in this population. However, discrepancies in the guidelines for perioperative evaluation and risk mitigation strategies for the ischemic cardiac burden are present in the current literature. This is a review of the available data regarding perioperative evaluation, revascularization tactics, postoperative management, and survival rate that patients with different grades of coronary artery disease present after lung transplantation.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: